Literature DB >> 17960065

Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series.

Yasuhiko Sugawara1, Sumihito Tamura, Masatoshi Makuuchi.   

Abstract

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the major indications for living donor liver transplantation (LDLT). Unlike in deceased donor liver transplantation, however, there exist no universally adopted selection criteria for the potential candidates with HCC in LDLT. Our institutional guideline for HCC in LDLT has been up to 5 nodules with a maximum diameter of 5 cm (5-5 rule).
METHODS: A total of 78 adult patients underwent adult living donor liver transplantation at University of Tokyo between April 1996 and October 2005.
RESULTS: Overall and recurrence-free survival at 5 years after transplantation were 75 and 90%, respectively, with a median follow-up of 2 years. When stratified by the 5-5 rule, recurrence-free survival at 3 years for patients fulfilling the criteria and those exceeding the criteria was 94 and 50%, respectively.
CONCLUSIONS: In LDLT, the indication for HCC might be expanded from the Milan criteria, with equivalent outcomes. Further study, however, is necessary to justify the general application of the 5-5 rule. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17960065     DOI: 10.1159/000106910

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  85 in total

1.  Liver transplant for patients outside Milan criteria.

Authors:  Giovanni Battista Levi Sandri; Michel Rayar; Xingshun Qi; Pierleone Lucatelli
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-26

2.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

3.  Living donor liver transplantation for hepatocellular carcinoma: defining criteria to extend indications.

Authors:  Irinel Popescu
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

4.  Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.

Authors:  Seung Duk Lee; Bora Lee; Seong Hoon Kim; Jungnam Joo; Seok-Ki Kim; Young-Kyu Kim; Sang-Jae Park
Journal:  World J Transplant       Date:  2016-06-24

Review 5.  Living donor liver transplantation: eliminating the wait for death in end-stage liver disease?

Authors:  Robert A Fisher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-15       Impact factor: 46.802

6.  Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Naoko Kamo; Toshimi Kaido; Shintaro Yagi; Hideaki Okajima; Shinji Uemoto
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

7.  Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.

Authors:  Ping Wan; Jian-Jun Zhang; Qi-Gen Li; Ning Xu; Ming Zhang; Xiao-Song Chen; Long-Zhi Han; Qiang Xia
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 8.  Liver transplantation for hepatocellular carcinoma.

Authors:  See Ching Chan
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 10.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.